Association of MG53 with presence of type 2 diabetes mellitus, glycemic control, and diabetic complications.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
02
06
2023
accepted:
27
08
2023
medline:
14
9
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
epublish
Résumé
Mitsugumin 53 (MG53) is a myokine that acts as a membrane repair protein in tissues. Data on the effect of MG53 on insulin signaling and type 2 diabetes mellitus (T2 DM) are still unknown; most are from preclinical studies. Nevertheless, some researchers have argued that it may be a new pathogenic factor, and therapies targeting MG53 may be a new avenue for T2 DM. Our study aims to evaluate the relationship of circulating MG53 levels with the presence of diabetes, diabetic complications, and glycemic control. We conducted a case-control study with 107 patients with T2 DM and 105 subjects without insulin resistance-related disease. Concurrent blood samples were used for serum MG53 levels and other biochemical laboratory data. MG53 concentration was measured using Human-MG53, an enzyme-linked immunosorbent assay kit (Cat# CSB-EL024511HU). We found no difference in MG53 levels between the diabetic and control groups (p = 0.914). Furthermore, when the subjects were divided into tertiles according to their MG53 levels, we did not find any difference between the groups in terms of the presence of diabetes (p = 0.981). Additionally, no correlation was observed between weight, BMI, waist circumference, systolic and diastolic blood pressure, fasting blood glucose, HbA1c, albumin excretion in the urine, e-GFR levels, and MG53. Finally, MG53 levels were similar between the groups with and without microvascular and macrovascular complications of diabetes. Our research finding provides insightful clinical evidence of lack of association between the levels of MG53 and T2 DM or glycemic control, at least in the studied population of Turkeys ethnicity. However, further clinical studies are warranted to establish solid evidence of the link between MG53, insulin resistance and glycemic control in a wider population elsewhere in the world.
Identifiants
pubmed: 37699054
doi: 10.1371/journal.pone.0291333
pii: PONE-D-23-16760
pmc: PMC10497120
doi:
Substances chimiques
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0291333Informations de copyright
Copyright: © 2023 Andaç et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Commun. 2013;4:2354
pubmed: 23965929
Nature. 1994 Nov 10;372(6502):182-6
pubmed: 7969452
Sci Transl Med. 2012 Jun 20;4(139):139ra85
pubmed: 22723464
Diabetologia. 2014 Jun;57(6):1087-99
pubmed: 24676645
Circulation. 2010 Jun 15;121(23):2565-74
pubmed: 20516375
Cell Biosci. 2021 Jun 28;11(1):115
pubmed: 34183055
Front Cardiovasc Med. 2020 Oct 28;7:596107
pubmed: 33195485
Circulation. 2019 Feb 12;139(7):901-914
pubmed: 30586741
Kidney Int. 2022 Jan;101(1):119-130
pubmed: 34757120
J Clin Invest. 1997 Mar 1;99(5):861-6
pubmed: 9062343
Immunopharmacol Immunotoxicol. 2022 Aug;44(4):484-491
pubmed: 35438597
Mol Pharmacol. 2017 Sep;92(3):211-218
pubmed: 28432201
PLoS One. 2015 May 07;10(5):e0124128
pubmed: 25950605
Circulation. 2019 Aug 6;140(6):e186-e187
pubmed: 31381425
Diabetes. 2020 May;69(5):1052-1064
pubmed: 32139593
Nature. 2013 Feb 21;494(7437):375-9
pubmed: 23354051
Circulation. 2015 Mar 3;131(9):795-804
pubmed: 25637627
Diabetes Metab. 2022 Mar;48(2):101292
pubmed: 34678488
N Engl J Med. 1990 Jan 25;322(4):223-8
pubmed: 2403659
J Diabetes Res. 2016;2016:1564386
pubmed: 27843952
Nat Commun. 2019 Oct 11;10(1):4659
pubmed: 31604915
Nat Cell Biol. 2009 Jan;11(1):56-64
pubmed: 19043407
Diabetes Care. 2017 Jan;40(1):136-154
pubmed: 27999003
Popul Health Metr. 2010 Oct 22;8:29
pubmed: 20969750
Sheng Li Xue Bao. 2016 Aug 25;68(4):505-16
pubmed: 27546510
BMB Rep. 2016 Aug;49(8):414-23
pubmed: 27174502
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Dec 20;95:109684
pubmed: 31260721
PLoS One. 2021 Feb 10;16(2):e0245179
pubmed: 33566837
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
Nat Rev Endocrinol. 2016 Oct;12(10):616-22
pubmed: 27388988